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Should heart age calculators be used
alongside absolute cardiovascular disease
risk assessment?
Carissa Bonner1,2* , Katy Bell1,3, Jesse Jansen1,2, Paul Glasziou1,3, Les Irwig1, Jenny Doust1,3 and Kirsten McCaffery1,2
Abstract
Background: National estimates of ‘heart age’ by government health organisations in the US, UK and China show
most people have an older heart age than current age. While most heart age calculators are promoted as a
communication tool for lifestyle change, they may also be used to justify medication when clinical guidelines
advocate their use alongside absolute risk assessment. However, only those at high absolute risk of a heart
attack or stroke are likely to benefit from medication, and it is not always clear how heart age relates to
absolute risk. This article aims to: 1) explain how heart age calculation methods relate to absolute risk guidelines; 2)
summarise research investigating whether heart age improves risk communication; and 3) discuss implications for the
use of medication and shared decision making in clinical practice.
Main body: There is a large and growing number of heart age models and online calculators, but the clinical meaning
of an older heart age result is highly variable. An older heart age result may indicate low, moderate or high absolute
risk of a heart attack or stroke in the next 5-10 years, and the same individual may receive a younger or older heart age
result depending on which calculator is used. Heart age may help doctors convey the need to change lifestyle, but it
cannot help patients make an informed choice about medication to reduce CVD risk.
Conclusion: Interactive heart age tools may be helpful as a communication tool to initiate lifestyle change to reduce
risk factors. However, absolute risk should be used instead of heart age to enable informed decision making about
medication, to avoid unnecessary treatment of low risk people. Evidence-based decision aids that improve patient
understanding of absolute risk should be considered as alternatives to heart age calculators for lifestyle and medication
decisions.
Keywords: Cardiovascular risk, Risk assessment, Heart age, Overtreatment, Overdiagnosis
Background
A recent newspaper front page in the UK exclaimed “4
in 5 have a heart that is older than they are”, with similar
media reports in the US that “40% of Americans had
hearts that were five or more years older than their ac-
tual ages” [1, 2]. These alarming statistics might suggest
a need for mass medicalisation of the population with
statins and blood pressure lowering drugs, but what does
it really mean to have an older heart age? This article
explores the idea that the heart age concept is highly
variable and potentially misleading when it comes to
deciding about whether or not to take preventive medi-
cation [3, 4]. This is in contrast to guidelines advocating
the use of heart age alongside absolute risk assessment
for medication decision making [5]. The absolute risk of
a heart attack or stroke is a better way to enable
informed decision making and target treatment to those
at highest risk who are most likely to benefit; while at
the same time avoiding unnecessary labelling and treat-
ment of low risk people [6, 7]. There is increasing aware-
ness that we might be overdiagnosing and overtreating
healthy, asymptomatic people, and that ‘less is more’
when the harms of an intervention outweigh the
benefits [8]. Concerns about ‘mass medicalisation’ for
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cardiovascular disease (CVD) prevention have already
been voiced following new guidelines in the UK and the
US advocating much lower absolute risk thresholds for
medication: halved from 20% to 10% over 10 years in the
UK; and even lower to 7.5% in the US [9, 10].
This article aims to: 1) provide an overview of heart
age calculation methods used in connection to absolute
risk guidelines; 2) summarise research investigating
whether heart age improves risk communication; and 3)
discuss implications for the use of medication and
shared decision making in clinical practice. We argue
that the increasingly popular concept of heart age may
contribute to mass medicalisation if used for the wrong
purpose, and provide directions for future research to
explore alternative risk communication formats that
enhance informed decision making.
Main text
What is heart age?
Heart age generally involves an assessment of risk
factors (e.g. age, sex, blood pressure, cholesterol, smok-
ing and diabetes status) to estimate an individual’s risk
of CVD, which is then compared to a defined ‘ideal’
[11]. A heart age that is older than current age indicates
elevated but modifiable risk, even if the absolute risk of
a CVD event in the next 5-10 years is low [5, 11, 12].
For example, the New Zealand Heart Foundation
(NZHF) assesses absolute risk in the next 5 years, and
compares this to the age at which a person would reach
the same absolute risk result if they did not smoke, had
systolic blood pressure of 120 mmHg and total/HDL
cholesterol ratio of 4 [11]. Figure 1 shows how a 57 year
old woman with elevated cholesterol would be assessed
as having a low 5-year absolute risk of 4%, but an older
heart age of 64, since a woman with ‘ideal’ risk factor
levels would not reach 4% risk for another 7 years
(www.knowyournumbers.co.nz). This ‘ideal’ absolute risk
approach is currently used to promote clinical practice
guidelines in New Zealand and the UK [5, 11] but alter-
native methods compare a patient’s risk factors to the
average of the population [13, 14], or use the results of
scans rather than absolute risk models [3].
Where is heart age used?
While New Zealand and the UK are the countries that
most clearly link heart age to clinical medication guide-
lines [5, 11] millions of heart age assessments have been
reported internationally in the academic literature. This
includes a large study across 13 countries [15] and popu-
lation estimates of heart age by government health orga-
nisations in the US (Centers for Disease Control and
Prevention) [16], UK (National Health Service) [17] and
China (National Center for Cardiovascular Disease) [18].
In the US, heart age calculators are being promoted by
the federal government, local health organisations and
industry, though guidelines do not yet appear to expli-
citly link them to medication recommendations. The
Framingham study published a heart age assessment
algorithm in 2008 [19], which was developed into an
online tool on the Centers for Disease Control and Pre-
vention (CDC) website [20]. This calculator is promoted
by the current Million Hearts campaign (federally run
through the US Department of Health and Human Ser-
vices, co-led by the CDC and the Centers for Medicare
& Medicaid Services) as a resource for doctors to use
with their patients [21]. The CDC published a national
estimate of 69.1 million “older” heart age assessments
based on this algorithm in 2015 [16], highlighting socio-
economic and racial disparities which received some
news coverage [2]. Heart age calculators are currently
promoted by smaller organisations using various models
and presentation formats, including university institutions,
medical clinics and private companies [22–24]. More
broadly, in 2009 Unilever partnered with the World Heart
Federation to promote its heart age calculator and
cholesterol-lowering food products internationally, leading
to top Google rankings for “heart age” and at least 2.7 mil-
lion users [15, 25]. In Europe, vascular age for the SCORE
model was published in 2010 [26], and a cardiovascular
risk age calculator is recommended to communicate the
need for lifestyle change to younger adults in 2016 cardio-
vascular prevention guidelines [27].
How does heart age fit into CVD risk management?
There are two distinct, and complementary, ways to
manage CVD risk: lifestyle change to improve diet and
physical activity, and medication to lower blood pres-
sure and cholesterol. Motivating patients with CVD risk
factors to change their lifestyle is important at any age,
and this is where the heart age concept has been
promoted as a potentially useful tool [5, 11, 12]. For ex-
ample, a 25-year-old obese smoker needs to be moti-
vated to give up smoking and improve their diet and
exercise. Their chance of having a heart attack in the
next few years will be low due to their young age, so
telling them that their heart age is 35 may be a more
compelling way to convey the need for lifestyle change.
If they still have CVD risk factors at the age of 40, a
different approach is needed to make decisions about
the benefits of commencing blood pressure and
cholesterol-lowering medication. This requires an
assessment of the absolute risk of a CVD event (e.g.
heart attack or stroke) in the next 5 to 10 years, in
order to estimate the benefit an individual patient is
likely to gain from taking medication [28].
Problems may arise if heart age is used to inform
medication decisions rather than motivate lifestyle
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change. This is increasingly likely as more heart age
assessment methods are developed and implemented
alongside medication guidelines based on absolute
risk [3, 5, 11]. There are now multiple heart age cal-
culators linked to clinical practice guidelines and
available to the public, conveying conflicting messages
about risk and medication. It is essential that doctors
and patients understand the assumptions behind these
heart age calculators and how they relate to absolute
risk-based medication guidelines.
Fig. 1 Two heart age calculator results for low absolute risk but older heart age (for Case 1 in Table 1: 57 year old woman with elevated
cholesterol and no other risk factors; www.knowyournumbers.co.nz; www.nhs.uk/tools/pages/heartage.aspx) (2017 version)
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Does heart age improve risk communication?
It can be challenging to communicate CVD risk to pa-
tients [12, 29]. Heart age has been promoted as a poten-
tially useful way to explain lifetime CVD risk, particularly
for younger people who need to change their lifestyle but
are at low risk of a CVD event in the next few years [5,
11]. Clinical trials have shown that paper-based and online
risk assessments that include heart age can be beneficial
and improve risk factor management compared to stand-
ard care with verbal counselling about absolute risk [13,
14, 30]. However, these trials have not directly compared
heart age to absolute risk in the same visual format, so
although we can say that communicating heart age along-
side other CVD risk information can have an effect, we
can’t say whether that is due to using heart age instead of
absolute risk. Direct experimental comparisons in the
general population have found a recall benefit and more
emotional impact (e.g. increased worry) of heart age com-
pared to absolute risk, but no advantage for motivating
lifestyle change [4, 31, 32]. One of these studies found
increased patient misunderstandings about risk level and
concerns about credibility in the heart age group [4]. This
suggests a need for doctors to explain heart age within the
consultation to ensure patients adequately understand
their risk and its implications.
Overall, the research suggests that heart age is a more
emotionally engaging format for communicating CVD risk
to patients, and visual heart age formats may improve risk
factor management compared to standard care involving
verbal explanations of absolute risk. However, discussions
about medication need to be based on absolute risk rather
than heart age, because the likelihood of benefit depends
on the likelihood of risk. To make an informed decision
about medication, patients need to understand their base-
line absolute risk, because the probability of preventing
CVD with treatment is directly proportional to this [33,
34]. For example, 100 asymptomatic people with a 10-year
absolute risk of 10% would need to take statins for 10 years
in order to prevent 2 CVD events; the other 98 people
would not benefit (90 would not have an event and 8 would
have an event despite treatment). Not everyone will think it
is worth the cost, inconvenience and side effects to reduce
their individual risk from 10% to 8% (see Fig. 2). In this
context a shared decision making approach is particularly
important, which requires clear communication about the
absolute risk of a CVD event, and the absolute benefit of
medication [6, 10, 35]. Heart age may help doctors to con-
vey the need for lifestyle change at any level of absolute
risk, but it cannot help patients make an informed choice
about medication. Further research is needed to investigate
the effect of different risk calculation and presentation
methods: single versus multiple risk formats (such as com-
bining the percentage with verbal risk level and graphs
showing frequency), comparison to average versus ideal risk
factors, and use of absolute risk versus scan-based methods
of heart age calculation [3].
Why do heart age calculators give different
recommendations for the same patient?
The relationship between heart age and absolute risk
thresholds for medication can be very variable [5, 11].
Figure 1 demonstrates two different approaches. The
NZHF calculator (www.knowyournumbers.co.nz) explains
the relationship between absolute risk and heart age, with
medication thresholds based on 5-year absolute risk in
line with clinical guidelines. Maintaining ‘ideal’ risk factor
levels means that you stay below the medication thresh-
old even with increasing age. The Joint British Societies
(JBS) and National Health Service (NHS) heart age cal-
culators (www.jbs3risk.com/pages/risk_calculator.htm;
www.nhs.uk/tools/pages/heartage.aspx) estimate 10-year
absolute risk, with a separate calculation for heart age
based on an annual rate derived from the QRISK lifetime
model [4]. The approach to medication is quite different:
Fig. 2 Example of an absolute CVD risk tool from the Mayo Clinic Statin Choice decision aid. (for 10% risk of a CVD event over the next
10 years; https://statindecisionaid.mayoclinic.org/) (2017 version)
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users are informed that they may need medication based
on older heart age, even if their 10-year absolute risk is
low. The message conveyed here is that medication is an
option regardless of the absolute risk and benefit, which is
contrary to the absolute risk approach used in CVD pre-
vention guidelines.
To demonstrate this, we entered real patients’ risk fac-
tor values from a previous study of the NZHF calculator
into the 2017 version of the NHS calculator [36]. The
examples in Table 1 show how people with isolated risk
factors but low absolute risk would receive different
heart age results and medication information depending
on whether they use the NZHF or NHS calculator. For
example, Case 1 is a 57 year old non-smoking woman
with elevated cholesterol but ‘ideal’ blood pressure, body
mass index (BMI) in the healthy range, and no other risk
factors. She would receive an older heart age estimate
on both the NZHF (64) and NHS (60) websites, but a
low absolute risk result of 4% over 5 years or 5% over
10 years. Both the heart age and absolute risk numbers
vary due to different underlying models, but the key
issue to note for this paper is how “older heart age” is
related to medication recommendations. NZHF de-
scribes the risk category as mild and below the medi-
cation threshold based on absolute risk, while the
NHS calculator suggests that both cholesterol and
blood pressure medication may be needed, even
though the absolute risk is low in both cases. In con-
trast, if we entered the same risk factors into the
American College of Cardiology/American Heart As-
sociation (ACC/AHA) absolute risk calculator within
the Statin Choice decision aid (see Fig. 2) [37], we
would find that 100 people need to take cholesterol
medication for 10 years to prevent 1 heart attack, 3
would have a heart attack anyway, and the remaining
96 would never have had a heart attack in the first
place. Heart age cannot convey this information.
As well as using different CVD risk models, risk factor
thresholds may differ between calculators. Heart age is
based on comparison to an ‘ideal’, which requires the use
of multiple thresholds for individual risk factors. For ex-
ample, Case 1 is right on the threshold for blood pres-
sure (120 mmHg) so she is given the message that her
CVD risk is higher than normal on the NHS website;
whereas this is described as ‘ideal’ on the NZHF website
(2017 versions). The NHS website also says that choles-
terol medication may be needed despite being well
under the absolute risk medication threshold of 10%.
The heart age results in Table 1 are not widely different
in absolute terms, but there is a psychological difference
between having a younger and older heart age [36].
The examples above show how different heart age calcu-
lators can lead to different medication recommendations.
This suggests that patients with the same risk factors may
perceive their risk differently and receive different treatment
recommendations depending on which calculator their doc-
tor uses; potentially leading to unwarranted practice vari-
ation. These differences will become even greater when
using average rather than ideal risk factors [13, 14], or scan-
based methods of calculation rather than absolute risk [3].
How does heart age relate to medication decision making?
Using heart age to recommend medication is likely to
undermine the absolute risk approach for medication
Table 1 Examples of different heart age results for the same patient using different calculators
Patient profile Risk factors NZ: HF website UK: NHS website
Case 1 with elevated cholesterol but ‘ideal’ blood pressure
would receive an older heart age estimate on both
calculators, with two medications suggested for the
lower result
Age: 57
Sex: female
Systolic BP: 120
Chol ratio: 5.6
BMI: 24
Smoking: no
Diabetes: no
Older heart age (64)
5 yr. absolute risk = 4%
Mild risk below
medication threshold
Older heart age (60)
10 yr. absolute risk = 5%
May need chol & blood
pressure medication
Case 2 with elevated blood pressure but lower than
‘ideal’ cholesterol would receive an older heart age
on NZHF or the same heart age as current age on
NHS, with one medication suggested for the lower
result
Age: 62
Sex: male
Systolic BP: 130
Chol ratio: 3.5
BMI: 25
Smoking: no
Diabetes: no
Older heart age (63)
5 yr. absolute risk = 7%
Mild risk below
medication threshold
Same heart age (62)
10 yr. absolute risk = 9%
May need blood
pressure medication
Case 3 with obesity but ‘ideal’ blood pressure and
cholesterol would receive a younger heart age on
NZHF or an older heart age on NHS, with one
medication suggested for the higher result
Age: 48
Sex: female
Systolic BP: 120
Chol ratio: 4
BMI: 38
Smoking: no
Diabetes: no
Young heart age (< 48)
5 yr. absolute risk = 1%
Mild risk below
medication threshold
Older heart age (49)
10 yr. absolute risk = 2%
May need blood
pressure medication
Chol ratio total/HDL cholesterol ratio, BMI body mass index, NZ HF New Zealand Heart Foundation website (www.knowyournumbers.co.nz) (2017 version), UK NHS
United Kingdom National Health Service website (www.nhs.uk/tools/pages/heartage.aspx) (2017 version)
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decisions. The use of absolute risk to make treatment de-
cisions, instead of treating blood pressure and cholesterol
as isolated risk factors, allows medication to be targeted to
those at highest risk who are most likely to benefit by pre-
vention of a CVD event within 5-10 years. This approach
aims to prevent both over-treatment of low risk and
under-treatment of high risk individuals [28].
However, while JBS3 guidelines focus on absolute risk
assessment, they also recommend that medication
should be considered for people with low absolute risk
but older heart age than current age [5]. This is likely to
further lower the threshold for medication, and lead to
over-treatment of low risk individuals. National esti-
mates of heart age by government health organisations
in the US, UK and China show how this approach could
lead to ‘mass medicalisation’, as the majority of the gen-
eral population has an older heart age than current age.
The CDC found that every age strata had an older heart
age than current age on average, and 69.1 million
(43.7%) people aged 30-74 had a heart age > 5 years
older than current age [16]. The first 1.4 million users of
the UK National Health Service heart age tool indicated
that 79% had an older heart age than current age in
every age strata, including 69% of users under 40 years,
who are at low absolute risk of CVD [17]. The China
National Centre for Cardiovascular Disease analysed
heart age assessments for 18,214 people and found a
mean heart age 10 years older than current age, despite
a low 10-year CVD risk of 4% [18]. Similarly, an inter-
national study of 2.7 million people (31% UK) found an
average heart age 4 years older than current age [15].
Other risk format suggestions in the cardiovascular lit-
erature include relative risk, lifetime risk and percentiles
[12], but they all have the same problem as heart age:
they do not enable patients to make an informed choice
about medication benefits and harms based on current
research evidence. The 2016 European guidelines make
a clearer distinction between absolute risk for medica-
tion and heart age for lifestyle, stating directly: “both risk
age and lifetime risk are closer to relative than absolute
risk, and none provides an evidence base for drug treat-
ment decisions” [27]. Table 2 demonstrates how to avoid
the potential harms of using heart age to justify
medication.
What could we use instead of heart age?
The risk communication and decision aid literature
provides clear directions for alternative absolute risk for-
mats that could be used to explain CVD risk and the
benefits of both lifestyle and medication interventions.
This should be based on outcomes that are meaningful
to patients, focusing on the likelihood of experiencing a
CVD event rather than how far blood pressure or
cholesterol deviates from an arbitrary ‘ideal’ threshold
[6, 10, 35]. We know that the absolute risk of a CVD
event is easier to understand than relative risk, and that
multiple formats will cover different patient information
preferences and learning styles [38]. This should include
verbal explanation of the frequency of CVD events for a
given absolute risk result, and visual formats showing
the risks and benefits of all lifestyle and medication op-
tions in absolute terms [38]. Recent qualitative research
investigating such visual formats demonstrated how pa-
tients find absolute risk more meaningful when both
lifestyle and medication intervention effects can be
explored in relation to this (e.g. using the risk calculator
at http://chd.bestsciencemedicine.com/calc2.html) (2017
version) [39]. There is strong evidence from a Cochrane
systematic review of 105 randomised controlled trials
that providing this sort of information in the form of a
patient decision aid improves patient knowledge, accur-
acy of risk perception, doctor-patient communication,
and decision making that is consistent with individual
values and preferences [40]. For example, the Statin
Choice decision aid is an evidence-based, effective tool
that demonstrates how this can be done (Fig. 2), but it
could be improved by allowing lifestyle interventions to
be compared to medication options [37].
In the context of CVD prevention, where the majority
of asymptomatic people may be told they are high risk
based on heart age assessment, but the likelihood of
benefiting from medication depends on absolute risk,
clear communication to enable shared decision making
is especially important [41]. This requires population-
based absolute risk and treatment efficacy data to be
provided to the patient in a transparent way.
“When we offer statins, or any preventive treatment,
we are practicing a new kind of medicine, very
different to the doctor treating a head injury in A&E.
We are less like doctors, and more like a life insurance
Table 2 Why caution should be used when linking heart age to
medication
• Practice variation: Heart age results may be younger, the same or
older than current age for the same risk factors, depending on the
CVD risk model and ideal risk factor thresholds used to calculate
heart age; so it is important for doctors to understand the
assumptions behind these calculators in order to avoid unwarranted
practice variation.
• Uninformed decision making: Patients cannot understand the
chance of benefiting from preventive CVD medications such as
statins and blood pressure lowering drugs without knowing the
baseline absolute risk; so the relationship between heart age,
absolute risk and recommended medication thresholds needs to be
explained to enable informed decision making.
• Over-treatment: Using heart age to decide on the need for drugs
will lead to treatment of people who are very unlikely to experience
a CVD event in the next 5-10 years; so treatment decisions should
be made on the basis of absolute risk and not heart age.
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sales team: offering occasional benefits, many years
from now, in exchange for small ongoing costs. Patients
differ in what they want to pay now, in side effects or
inconvenience, and how much they care about
abstract future benefits. Crucially, the benefits and
disadvantages are so closely balanced that these
individual differences really matter.” (Ben Goldacre,
BMJ 2014) [10].
Conclusions
The heart age concept has intuitive appeal, but it can
also be used to justify treatment of low risk people who
are very unlikely to benefit in the short term from taking
medication. The assumptions behind heart age calcula-
tors need to be made clear and explicit so that both
doctors and patients can understand why they may get
different results on different calculators. They also need
to understand that this is a relative measure, where an
individual is compared to a specific definition of the
‘ideal’. Informed medication decisions should be based
on absolute risk and benefit rather than heart age, and
evidence-based communication formats such as decision
aids should be used to avoid uninformed decision
making and overtreatment of healthy, asymptomatic
people who are at low risk of a heart attack or stroke.
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